Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 300 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cardiac Transplant Disorder Clear all
Recruiting No phase listed Observational

The Impact of Renal Transplant on Coronary Microvascular Function Among Patients With Advanced Chronic Kidney Disease

NCT07222683
View directory record Official record
Conditions
Chronic Kidney Disease, Kidney Transplant, Coronary Microvascular Dysfunction (CMD), Inflammation
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Not applicable Interventional Results available

Intraoperative Echocardiography in Low-Risk CABG Surgery

NCT06154265
View directory record Official record
Conditions
Heart Diseases, Coronary Artery Disease, Chest Pain, Stenosis Coronary, STEMI
Interventions
TEE probe
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Cardiac Safe Transplants for Systemic Sclerosis

NCT03593902
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 2 Interventional

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

NCT00002657
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bleomycin sulfate, recombinant interferon alfa, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methotrexate, prednisone, vincristine sulfate, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2011
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 2Phase 3 Interventional

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

NCT00055510
View directory record Official record
Conditions
Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis
Interventions
BO-653
Drug
Lead sponsor
Chugai Pharma USA
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Phoenix, Arizona • Tucson, Arizona • Burlingame, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical and Hospital Stay Effects of Reiki and Manual Therapy After Open Heart Surgery

NCT05853250
View directory record Official record
Conditions
Coronary Artery Diseases, Valvular Heart Diseases
Interventions
Reiki/manual therapy
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 25, 2026, 7:33 PM EDT
Not listed No phase listed Observational

Utilizing Technology for Optimization of Pain Management and Mobilization in High Risk Cardiac Surgical ICU Patients

NCT04146727
View directory record Official record
Conditions
Transplant; Failure, Heart, Heart Failure, Congestive, Lung Transplant Failure
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
168 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Results available

Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery

NCT03939923
View directory record Official record
Conditions
Surgery, Coronary Artery Disease
Interventions
Rocuronium, Neostigmine, Glycopyrrolate, Sugammadex
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 25, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease

NCT05831085
View directory record Official record
Conditions
Coronary Artery Stenosis
Interventions
State-of-the-Art Percutaneous Coronary Intervention, standard CABG
Procedure
Lead sponsor
Duk-Woo Park, MD
Other
Eligibility
20 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Not listed No phase listed Observational

Genetic Predictors of Renal Dysfunction Following Heart Transplantation

NCT01686191
View directory record Official record
Conditions
Heart Transplantation, Chronic Renal Insufficiency
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 1 Interventional

Stem Cell Injection to Treat Heart Damage During Open Heart Surgery

NCT01557543
View directory record Official record
Conditions
Heart Disease, Ischemic Heart Disease, Coronary Artery Disease, Coronary Artery Disease (CAD)
Interventions
Cell Therapy
Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Results available

Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement

NCT01717209
View directory record Official record
Conditions
Heart Failure
Interventions
Nitric Oxide, Prostacyclin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 4 Interventional

Study of Unprotected Left Main Stenting Versus Bypass Surgery (LE MANS Study)

NCT00375063
View directory record Official record
Conditions
Coronary Artery Stenosis, Myocardial Revascularization, Myocardial Ischemia
Interventions
Percutaneous Coronary Intervention, Coronary Artery Bypass Grafting
Procedure
Lead sponsor
Ministry of Science and Higher Education, Poland
Government
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Bryn Mawr, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2006 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

NCT00300274
View directory record Official record
Conditions
Graft Rejection
Interventions
everolimus, mycophenolate mofetil, cyclosporine, corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 3 Interventional

Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation

NCT03341156
View directory record Official record
Conditions
Heart Disease End Stage, Heart Failure，Congestive
Interventions
Kcentra, Frozen Plasma Product, Human
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 25, 2026, 7:33 PM EDT
Completed No phase listed Observational

Inflammatory Biomarkers Predict Pulmonary Outcomes in Coronary Artery Bypass Grafting

NCT01366469
View directory record Official record
Conditions
Coronary Artery Disease, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in Patients Undergoing LVAD Implantation

NCT01442129
View directory record Official record
Conditions
Heart Failure, Cardiomyopathy, Ventricular Dysfunction
Interventions
MPC Intramyocardial injection, Control Solution
Biological
Lead sponsor
Deborah Ascheim
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Gainsville, Florida • Baltimore, Maryland • Minneapolis, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 4 Interventional Results available

Angiotensin II for Distributive Shock

NCT04904562
View directory record Official record
Conditions
Distributive Shock
Interventions
Angiotensin II, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Withdrawn Phase 4 Interventional

Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

NCT03026023
View directory record Official record
Conditions
Cardiac Transplant Disorder, Hepatitis C
Interventions
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin
Drug
Lead sponsor
Raymond T. Chung, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional

Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

NCT00041574
View directory record Official record
Conditions
Pulmonary Hypertension, Lung Disease, Sickle Cell Disease, Cardiac Transplant, Lung Transplant
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
5 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 25, 2026, 7:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation Using Computed Tomography Angiography (CTA) to Investigate and Detect Atherosclerotic Graft Disease (ELUCIDATE)

NCT00580008
View directory record Official record
Conditions
Arteriosclerosis of Coronary Artery Bypass Graft, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional

Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery

NCT00628264
View directory record Official record
Conditions
Cardiac Surgery, Coronary Artery Bypass Grafting, Valve Surgery, Kidney Injury
Interventions
AP214, Placebo
Drug
Lead sponsor
Action Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2009 · Synced Oct 25, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients

NCT06659952
View directory record Official record
Conditions
HIV Infection, Advanced End Stage Heart Failure
Interventions
HIV-positive heart transplant
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Not listed Phase 1 Interventional

Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection

NCT00050765
View directory record Official record
Conditions
Congestive Heart Failure, Coronary Artery Disease, Myocardial Infarction
Interventions
MyoCell™ Autologous Myoblasts
Drug
Lead sponsor
Bioheart, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2006 · Synced Oct 25, 2026, 7:33 PM EDT